EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Subcutaneous Trastuzumab (Herceptin<sup>®</sup>): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer

Russell Burcombe, Steve Chan, Richard Simcock, Kunal Samanta, Fran Percival, Peter Barrett-Lee

Advances in Breast Cancer Research · 2013 · 02 (04) · 133-140

DOI: 10.4236/abcr.2013.24022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Breast Cancer Research, 2013. Verfasst von Russell Burcombe und 5 weiteren Autor:innen. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Burcombe, R., Chan, S., Simcock, R., Samanta, K., Percival, F., & Barrett-Lee, P. (2013). Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer. Advances in Breast Cancer Research, 02(04), 133-140. https://doi.org/10.4236/abcr.2013.24022

Vancouver

Burcombe R, Chan S, Simcock R, Samanta K, Percival F, Barrett-Lee P. Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer. Advances in Breast Cancer Research. 2013;02(04):133-140. doi:10.4236/abcr.2013.24022

BibTeX
@article{Burcombe2013,
  author = {Burcombe, Russell and Chan, Steve and Simcock, Richard and Samanta, Kunal and Percival, Fran and Barrett-Lee, Peter},
  title = {Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer},
  journal = {Advances in Breast Cancer Research},
  year = {2013},
  volume = {02},
  number = {04},
  pages = {133--140},
  doi = {10.4236/abcr.2013.24022}
}
Kostenlos starten →